Senseonics Holdings, Inc. will release its second quarter 2026 financial results after market close on August 6, 2026. The medical technology company, focused on implantable Continuous Glucose Monitoring (CGM) Systems, scheduled the announcement to provide updates on its operational performance. The disclosure is critical for investors tracking the progress of its Eversense 365 and Eversense E3 CGM systems.

Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. Eastern Time on the same day. The call will be concurrently webcast, with the link available on Senseonics Holdings, Inc.'s website under the "Investor Relations" section. An archive of the webcast will be retained for future reference.

To participate in the conference call, investors can dial 1-833-354-6854 (US/Canada) or 1-785-838-9343 (International) using the passcode SENSQ2. Participants are advised to dial in approximately ten to five minutes prior to the start time.

Event Details

Senseonics Holdings, Inc. specializes in long-term implantable glucose management technology. Its CGM systems feature a sensor inserted under the skin that communicates with a smart transmitter, sending glucose data every five minutes to a mobile app.

Mizuho analyst Anthony Petrone maintained an Outperform rating for Senseonics Holdings while reducing the stock's price target to $18 from $20. The adjustment reflects a revised valuation outlook for the company listed on NASDAQ under the ticker SENS.

The rating affirmation indicates continued confidence in Senseonics Holdings' performance potential despite the lower price objective. The change in target price suggests a recalibration of expected returns rather than a shift in the fundamental investment thesis.

Investors will monitor Senseonics Holdings' progress against the new $18 target set by Mizuho. The Outperform stance implies the stock is expected to deliver above-market returns relative to its sector peers.